Tick season in Missouri: Prevention tips for hikers
Temperatures are getting warmer and grass is getting greener. You may feel a sudden urge to return to your favorite hiking trail this spring! But not so fast. Tick season in Missouri is also nearing its peak meaning you'll want to do a few things to prepare before hitting the trails.
Ticks forage for food using a strategy known as questing. They climb to the top of tall grass and wait for a mammal or a person to pass by. They are most common in high animal traffic areas, including along the edges of hiking trails.
There are 3 common types of ticks in the Ozarks. The most common type is the Lone Star Tick. The other common types are deer ticks and dog ticks. The most concerning as far as disease goes is the Lone Star tick.
Visit the Missouri Department of Conservation website for more on Missouri ticks.
The Lone Star tick is the main culprit of alpha-gal syndrome, a disease that causes an allergic reaction to eating red meat. Other tick-borne diseases include Rocky Mountain spotted fever, Lyme disease, Ehrlichiosis, and more.
So what can you do to lower your risk of a tick bite while enjoying nature? It's best to dress in long and tight clothing that covers your skin. A lightweight long-sleeve t-shirt is a good idea during the hot summer months. Long pants like jeans keep you from directly contacting grass where ticks can be lying in wait.
You can also wear long socks that are tighter against your skin. This helps prevent ticks from being able to latch onto your feet and ankles.
When looking at bug repellents, you'll want to buy a repellent that has a higher concentration of deet. Most name brands contain 25% deet, but certain brands contain up to 40%. Other companies offer pyrethran repellents, but be sure to only apply this kind to your clothes and not directly to your skin.
Ticks can be tricky to remove given their size, but you definitely want to remove them immediately. Use tweezers or a specific tick-removing tool when removing a tick. You'll want to pinch the tick as close to your skin as you can to avoid squeezing any of the tick's fluids into you (gross!).
There are symptoms to watch out for after a tick bites you. Look for a reddish ring around the bite site, rash, headache, and aching muscles and joints. Seek medical attention if you notice these symptoms following a tick bite.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
4 hours ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
Hims & Hers Health, Inc. (HIMS) closed at $55.25 in the latest trading session, marking a -2.83% move from the prior day. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Coming into today, shares of the company had gained 2.99% in the past month. In that same time, the Medical sector gained 3.49%, while the S&P 500 gained 6.29%. Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's upcoming EPS is projected at $0.17, signifying a 183.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $551.84 million, up 74.83% from the year-ago period. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.73 per share and a revenue of $2.34 billion, representing changes of +170.37% and +58.31%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.66% upward. Hims & Hers Health, Inc. is currently a Zacks Rank #2 (Buy). From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 77.39. This valuation marks a premium compared to its industry's average Forward P/E of 27.09. Meanwhile, HIMS's PEG ratio is currently 2.12. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Info Systems industry had an average PEG ratio of 2.12 as trading concluded yesterday. The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 70, which puts it in the top 29% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
The importance of donating blood to help others
WACO, Texas (FOX 44) – We at FOX 44 are teaming up with Carter BloodCare to host a Blood Drive this Friday, June 13th! With this, we would like to provide you with some additional information on the importance of donating. Carter BloodCare consultant Jessica Amara is here to share more. You can watch our interview in the video above. While no appointment is necessary for our Blood Drive, you can schedule an appointment online here. You can also scan the QR code below to sign up. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.